UNSPSC 51382202: Talniflumate

This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C21H13F3N2O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier JFK78S0U9S, chemically known as 3-pyridinecarboxylic acid, 2-((3-(trifluoromethyl)phenyl)amino)-, 1,3-dihydro-3-oxo-1-isobenzofuranyl ester but generally known as talniflumate, which bears US NIH Compound Identifier 48229. European Medicines Agency schedules Talniflumate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10810MIG.

UNSPSC 51382202 Talniflumate is a Commodity code that in recent state and local procurement records captures naloxone, drug deactivation systems, generic multi-source pharmaceuticals, and over-the-counter products procured by health authorities and cooperative purchasing alliances. State and local governments are acquiring these products primarily through health and human services agencies, county health departments, and multistate cooperative purchasing vehicles to support emergency medical response, community health initiatives, and broader pharmacy benefit programs. Issuing bodies span county health systems (Seminole County, Florida), state health and human services commissions (Texas HHS), and multistate cooperative purchasing alliances serving state and local facilities across multiple jurisdictions (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP, serving Minnesota, Oregon, and participating states).

Activity is concentrated in Florida, Texas, and the Upper Midwest. Seminole County, Florida issued IFB 60459723LAS (response deadline Jul 26, 2023) seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida, on a two-year contract with optional one-year renewal and a three-month probationary termination window. The Texas Health and Human Services Commission posted RFI HHS0017013 (response deadline Apr 3, 2026) as preliminary market intelligence to explore direct-to-manufacturer prescription fulfillment models outside traditional pharmacy benefit manager arrangements, signaling intent to develop formal competitive solicitation strategy for downstream RFP issuance. MMCAP, administered by the Minnesota Department of Administration, released RFP S1070000015802 (response deadline Mar 26, 2026) to establish multi-year contracts for generic pharmaceuticals and OTC products distributed through three authorized wholesalers (AmerisourceBergen/Cencora, Cardinal Health, Morris & Dickson) to participating state and local government facilities, with contract effectiveness set for Jul 1, 2026, and evaluation weighted 75 percent on price competitiveness, 10 percent on fixed pricing terms, and remaining points on administrative compliance, EDI capability, and administrative-fee agreement.